ライフサイエンスコーパス: pancreatic polypeptide

1 ocytochemistry (e.g., insulin, glucagon, and pancreatic polypeptide).

2 n, peptide YY, cholecystokinin, insulin, and pancreatic polypeptide.

3 secretion by the gut hormones peptide YY and pancreatic polypeptide.

4 ls also produced glucagon, somatostatin, and pancreatic polypeptide.

5 a levels of epinephrine, norepinephrine, and pancreatic polypeptide.

6 rmones: insulin, glucagon, somatostatin, and pancreatic polypeptide.

7 +/- 424 pmol/l, respectively; P < 0.05) and pancreatic polypeptide (97 +/- 32 and 98 +/- 8 vs. 223 +

8 Administration of either pancreatic polypeptide (a strong agonist of the receptor

9 proach, the small, well-folded protein avian pancreatic polypeptide acts as a scaffold to present and

10 re, the interaction of receptor mutants with pancreatic polypeptide analogs was studied through doubl

11 the model PEGylated peptides, 20K PEGylated-Pancreatic Polypeptide analogue (PPA) and 20K PEGylated-

12 ic hormones insulin, glucagon, somatostatin, pancreatic polypeptide and ghrelin.

13 2 responses of epinephrine, norepinephrine, pancreatic polypeptide and MSNA compared to day 1 cortis

14 detected the presence of insulin, glucagon, pancreatic polypeptide and somatostatin-producing cells

15 ities blunted key autonomic (epinephrine and pancreatic polypeptide) and metabolic (endogenous glucos

16 in, glucagon, vasoactive intestinal peptide, pancreatic polypeptide, and 24-hour urinary 5-hydroxyind

17 and high-density lipoprotein (HDL), leptin, pancreatic polypeptide, and amylin.

18 e, norepinephrine, glucagon, growth hormone, pancreatic polypeptide, and cortisol levels, was signifi

19 e AR42J cells to differentiate into insulin, pancreatic polypeptide, and glucagon-positive cells.

20 ents in subsequent glucagon, growth hormone, pancreatic polypeptide, and muscle sympathetic nerve act

21 de YY (PYY), oxyntomodulin (enteroglucagon), pancreatic polypeptide, and somatostatin.

22 l face of the small yet stable protein avian pancreatic polypeptide (aPP).

23 es encoding receptors with high affinity for pancreatic polypeptide are not clustered with the genes

24 5%), beta-cells (92%), delta-cells (1%), and pancreatic polypeptide cells (2%).

25 conversion of beta-cells lacking Abcc8 into pancreatic polypeptide cells but not to alpha- or delta-

26 subunits were expressed in alpha, beta, and pancreatic polypeptide cells, whereas kainate receptors

27 -c-peptide, fibrinogen, alpha-1-antitrypsin, pancreatic polypeptide, complement C3, vitronectin, cort

28 and percentage body fat) and fasting plasma pancreatic polypeptide concentrations (both before and a

29 dies resulted in significantly higher plasma pancreatic polypeptide concentrations compared with the

30 Plasma insulin and pancreatic polypeptide concentrations peaked at 250% and

31 Adjustment for fasting plasma pancreatic polypeptide concentrations, a marker of paras

32 hologic dedifferentiation of beta-cells to a pancreatic polypeptide-fold hormone-positive state.

33 ease in gastric acid output, a rise in serum pancreatic polypeptide following sham feeding, and prese

34 pha-helix onto a small stable protein, avian pancreatic polypeptide, generated a helical 30-amino-aci

35 s, steady state epinephrine, norepinephrine, pancreatic polypeptide, glucagon, ACTH and muscle sympat

36 2 steady state epinephrine, norepinephrine, pancreatic polypeptide, glucagon, growth hormone, and mu

37 and fasting plasma concentrations of GLP-1, pancreatic polypeptide, glucose, and insulin.

38 an Y4 receptor (hY4R) interaction with human pancreatic polypeptide (hPP) is crucial, not only for un

39 y [Leu(31),Pro(34)]NPY, NPY(13-36) and human pancreatic polypeptide (hPP).

40 This compound attenuated bovine pancreatic polypeptide induced food intake in rats but f

41 and masking any binding to Y4 using 1 nM rat pancreatic polypeptide left a small amount of binding re

42 YY, glucagon-like peptide 1, oxyntomodulin, pancreatic polypeptide, leptin, and adiponectin concentr

43 ect group of patients identified an elevated pancreatic polypeptide level and pancreatic tail mass le

44 ypoglycemia-induced increase in the arterial pancreatic polypeptide level.

45 Pancreatic polypeptide levels tended to increase in CON

46 ine, glucagon, growth hormone, cortisol, and pancreatic polypeptide levels were similarly significant

47 rine, muscle sympathetic nerve activity, and pancreatic polypeptide), neuroendocrine (glucagon and gr

48 dditional significant blunting (P < 0.01) of pancreatic polypeptide, norepinephrine, growth hormone,

49 her reduced the epinephrine (P = 0.0001) and pancreatic polypeptide (P = 0.0030) responses, tended to

50 e (P = 0.0027), norepinephrine (P = 0.0007), pancreatic polypeptide (P = 0.0030), and neurogenic symp

51 0), perhaps norepinephrine (P = 0.0838), and pancreatic polypeptide (P = 0.0034) responses to hypogly

52 (P = 0.0094), epinephrine (P = 0.0063), and pancreatic polypeptide (P = 0.0046) responses to stepped

53 = 0.6270), neurogenic symptom (P = 0.6470), pancreatic polypeptide (P = 0.0629), or glucagon (P = 0.

54 a-cell-associated genes (IAPP [islet amyloid pancreatic polypeptide], PDX-1 [pancreatic and duodenal

55 , 12.1%+/-0.7% somatostatin, and 1.5%+/-0.2% pancreatic polypeptide-positive cells.

56 absence of peptide YY with the exception of pancreatic polypeptide (PP) cells, indicating that pepti

57 rticularly the less abundant delta and gamma/pancreatic polypeptide (PP) cells.

58 Neuropeptide Y (NPY) and pancreatic polypeptide (PP) control central and peripher

59 ects of peptides of the neuropeptide Y (NPY)/pancreatic polypeptide (PP) family on synaptic transmiss

60 (PYY), glucagon-like-peptide-1 (GLP-1), and pancreatic polypeptide (PP) in humans and rodents follow

61 Pancreatic polypeptide (PP) is a regulatory peptide that

62 Pancreatic polypeptide (PP) is released from the pancrea

63 the pancreas as assessed by increased plasma pancreatic polypeptide (PP) levels (delta = 135.0 +/- 36

64 Pancreatic polypeptide (PP) microinjected into the dorsa

65 malian neuropeptide Y (NPY)/peptide YY (PYY)/pancreatic polypeptide (PP) receptors comprises several

66 To determine if pancreatic polypeptide (PP) secretion is likewise involv

67 example, in the neuropeptide Y (NPY) family, pancreatic polypeptide (PP) shows significant structural

68 perinsulinemia and elevated plasma levels of pancreatic polypeptide (PP), an islet hormone considered

69 neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP), are found in the central an

70 an Y4 receptor (Y4R) and its cognate ligand, pancreatic polypeptide (PP), are involved in the regulat

71 he related peptide YY(3-36) (PYY(3-36)), and pancreatic polypeptide (PP), important modulators of ARC

72 eptide 1 analogue, cholecystokinin (CCK) and pancreatic polypeptide (PP).

73 on preferences for NPY, peptide YY (PYY), or pancreatic polypeptide (PP).

74 he endocrine peptides, peptide YY (PYY), and pancreatic polypeptide (PP).

75 ffinity (Kd = 2.8 nM) for 125I-labeled human pancreatic polypeptide (PP).

76 31, Pro34]NPY (Y1/Y5), NPY (Y3/Y1/Y5/Y2) and pancreatic polypeptide (PP, Y4) injected i.c. at 500 ng

77 ribed Y1, Y2 and Y3 NPY receptors and the Y4 pancreatic polypeptide- (PP-) preferring receptor.

78 Pancreatic polypeptides (PPs) such as neuropeptide Y (NP

79 Peptide YY (PYY) and pancreatic polypeptide (PPY) are members of the neuropep

80 ells, somatostatin-producing delta cells and pancreatic polypeptide-producing PP cells.

81 ny of the normal islet cell types except for pancreatic-polypeptide-producing cells.

82 as assessed by 70% reductions of the plasma pancreatic polypeptide response and epinephrine response

83 tion was measured by gastric acid output and pancreatic polypeptide response to sham feeding.

84 th hormone, epinephrine, norepinephrine, and pancreatic polypeptide responses during day 2 exercise w

85 r of the transplanted groups (IH and IP) had pancreatic polypeptide responses.

86 ephrine), and parasympathetic neural (plasma pancreatic polypeptide)-responses to hypoglycemia were n

87 exin neurons, we examined the effects of rat pancreatic polypeptide (rPP), a Y4-selective ligand, or

88 5% of NETs demonstrated focal positivity for pancreatic polypeptide, somatostatin, insulin, and/or gl

89 Pancreatic polypeptide was significantly lower (P < 0.05

90 Modeling based on the avian pancreatic polypeptide X-ray structure suggested that an

91 Guinea-pig neuropeptide Y1 and rat pancreatic polypeptide Y4 receptors expressed in Chinese